AVLSA
SPRO icon

Atlas Venture Life Science Advisors’s Spero Therapeutics SPRO Stock Holding History

Atlas Venture Life Science Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-305,255
Closed -$220K – 13
2025
Q1 		$220K Hold
305,255
– – 0.04% 13
2024
Q4 		$314K Sell
305,255
-97,630
-24% -$116K 0.04% 13
2024
Q3 		$540K Sell
402,885
-132,451
-25% -$178K 0.05% 14
2024
Q2 		$696K Sell
535,336
-72,277
-12% -$109K 0.07% 15
2024
Q1 		$1.05M Sell
607,613
-405,825
-40% -$636K 0.1% 16
2023
Q4 		$1.49M Hold
1,013,438
– – 0.18% 16
2023
Q3 		$1.23M Hold
1,013,438
– – 0.19% 15
2023
Q2 		$1.47M Sell
1,013,438
-17,722
-2% -$30.3K 0.18% 15
2023
Q1 		$1.5M Hold
1,031,160
– – 0.2% 16
2022
Q4 		$1.78M Hold
1,031,160
– – 0.21% 16
2022
Q3 		$2.06M Hold
1,031,160
– – 0.23% 16
2022
Q2 		$764K Hold
1,031,160
– – 0.13% 16
2022
Q1 		$8.97M Hold
1,031,160
– – 1.13% 12
2021
Q4 		$16.5M Buy
+1,031,160
New +$16.4M 1.52% 11

Other funds holding SPRO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Atlas Venture Life Science Advisors's SPRO Position: Q2 2025 in Review

Atlas Venture Life Science Advisors sold out of Spero Therapeutics (SPRO) in Q2 2025, closing a stake of 305,255 shares — an estimated $220K sold.

Atlas Venture Life Science Advisors first reported a position in SPRO in Q4 2021 and held it in 14 quarters. The position peaked at $16.5M in Q4 2021. 44 funds tracked by Wall St. Rank hold SPRO as of Q2 2025.

  • Atlas Venture Life Science Advisors reported no remaining Spero Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Atlas Venture Life Science Advisors sold 305,255 Spero Therapeutics shares in Q2 2025, an estimated $220K.
  • Atlas Venture Life Science Advisors first reported a position in Spero Therapeutics in Q4 2021 and held it in 14 quarters.
  • Atlas Venture Life Science Advisors's Spero Therapeutics position peaked at $16.5M in Q4 2021.
  • 44 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2025.

Based on Atlas Venture Life Science Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.